Compare Novartis AG (NVS) vs ProShares Ultra Gold ETF (UGL) Price & Performance

Novartis AGTrade

ProShares Ultra Gold ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs ProShares Ultra Gold ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while ProShares Ultra Gold ETF trades at $45. The key difference: Novartis AG pays a 3.17% dividend while ProShares Ultra Gold ETF pays none, and Novartis AG is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.

	NVS	UGL
Market Cap	$290.25B	—
Sector	Health	Leveraged / Inverse
52-Week High	$168.62	$85.62
52-Week Low	$113.50	$33.59
Enterprise Value	$330.27B	—
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.

The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.

ProShares Ultra Gold ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 5 days agoBullish View details →

UGL

ProShares Ultra Gold and UltraShort Gold offer opposite 2x gold exposure but suit different tactical bets.24/7 Wall Street · 4 days agoNeutral Leveraged gold ETFs like UGL and GLL suffer significant decay in volatile markets, reducing expected returns.24/7 Wall Street · 4 days agoBearish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.